[A densitometric assessment of skeletal mineral levels in prostate cancer patients treated with hormones].
An assessment of the densitometry data on 76 patients established a progressively falling level of minerals in the skeleton as a result of treatment with hormones for prostate cancer. The basal mineral levels had been identified by means of dual-energy X-ray absorptiometry. While said changes were immediately caused by maximum androgen deprivation, tumor influence and medication contributed too.
Kharchenko
V P
VP
Kaprin
A D
AD
Adzhamatov
S R
SR
D015502:Absorptiometry, Photon; D000368:Aged; D000726:Androgen Antagonists / Q000008:administration & dosage / Q000009:adverse effects*; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000009:adverse effects*; D018488:Bone Demineralization, Pathologic / Q000139:chemically induced / Q000000981:diagnostic imaging* / Q000378:metabolism; D015519:Bone Density / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal